Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data

ÜSKÜDAR CANSU, DÖNDÜ; ÜSKÜDAR TEKE, HAVA; TEMEL, TUNCER; Erturk, Adem; Kahraman, Osman; KORKMAZ, CENGİZ

doi:10.1016/j.jnma.2018.10.003

Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data

Copy For Citation

ÜSKÜDAR CANSU D., ÜSKÜDAR TEKE H., TEMEL T., Erturk A., Kahraman O., KORKMAZ C.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.111, no.3, pp.262-269, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 111 Issue: 3
Publication Date: 2019
Doi Number: 10.1016/j.jnma.2018.10.003
Journal Name: JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.262-269
Keywords: Ankylosing spondylitis, Anti-TNF-alfa, Paradoxical adverse events, Inflammatory bowel disease, NECROSIS FACTOR THERAPY, JUVENILE IDIOPATHIC ARTHRITIS, EXTRAARTICULAR MANIFESTATIONS, GUT INFLAMMATION, ADVERSE EVENTS, NEW-ONSET, SPONDYLOARTHROPATHIES
Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: The aim of this study was to determine whether there is any association with anti-tumor necrosis factor (TNF) agent administration and development of new-onset inflammatory bowel disease (IBD) in ankylosing spondylitis (AS) patients.